Abdallah, Al-Ola Lesokhin, Alexander Wrobel, Tomasz Jamroziak, Krzysztof Dytfeld, Dominik Touzeau, Cyrille Suvannasankha, Attaya Leleu, Xavier Silbermann, Rebecca Khan, Abdullah M.
...
Published in
Frontiers in Hematology
Purpose The phase I/II trial CheckMate 039 (NCT01592370) evaluated the safety, tolerability, and efficacy of nivolumab-daratumumab (ND) in patients with relapsed/refractory multiple myeloma (RRMM). Methods Patients with RRMM were randomized to receive ND with or without pomalidomide-dexamethasone (Pd) in cohort A and ND or D monotherapy in cohort B...
Schaaf, Christian W. Braunisch, Matthias C. Holzmann-Littig, Christopher Pfister, Frederick Hannemann, Liya Hausinger, Renate I. Verbeek, Mareike Schmaderer, Christoph Renders, Lutz Heemann, Uwe
...
Published in
Frontiers in Oncology
Background We determined the efficacy of free light chain (FLC) removal by regular dialysis equipment (high-flux filtration) with medium cutoff (MCO) membrane hemodialysis (HD) as an adjuvant treatment to standard chemotherapy for patients with acute kidney injury complicating multiple myeloma (MM) and its impact on further dialysis dependency. Met...
Forster, Stefan Radpour, Ramin Ochsenbein, Adrian F.
Published in
Frontiers in Immunology
Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post-germinal center B/plasma cells are the cause of myelomagenesis. The acquisition of additional chromosomal abnormalities and distinct mutations further promote the outgr...
Singh, Gurmukh Arinze, Nkechi Manthei, David M Plapp, Frederick V Bollag, Roni J
Published in
Laboratory medicine
Immunoglobulin monoclonal light chains (MLCs) in serum and urine are markers for monoclonal gammopathy and could serve as markers of minimal residual disease (MRD) in multiple myeloma (MM). Excretion of MLCs in urine is known to result in renal damage and shorter survival in patients with LC-predominant MM. Retrospective review of urine immunofixat...
Berghaus, Natalie Schreiner, Sarah Poos, Alexandra M Raab, Marc S Goldschmidt, Hartmut Mai, Elias K Salwender, Hans-Jürgen Bernhard, Helga Thurner, Lorenz Müller-Tidow, Carsten
...
Published in
The FEBS journal
Light chain amyloidosis (AL) is one of the most common forms of systemic amyloidosis and is caused by the deposition of insoluble fibrils derived from misfolded and aggregated immunoglobulin light chains (LC). To uncover the causes leading to this aggregation, we compared AL LC sequences with those of patients with the related disease multiple myel...
Liu, Liping Liu, Langni Liu, Rui Liu, Jing Cheng, Qian
Published in
Clinical and experimental pharmacology & physiology
The prognosis of multiple myeloma (MM) patients combined with renal insufficiency is poor. Renal fibrosis is an important pathological cause for MM patients combined with renal insufficiency. It is reported that epithelial-mesenchymal transition (EMT) of renal proximal tubular epithelial cells is an important mechanism in renal fibrosis. We specula...
Nishimura, Noriko Ono, Yoshihiro Shirouchi, Yuko Maruyama, Dai
Published in
Internal medicine (Tokyo, Japan)
Song, Seung Min Jeon, Junseok Jang, Hye Ryoun Kim, Kihyun Huh, Wooseong Kim, Yoon-Goo Lee, Jung Eun
Published in
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
The nephrotoxicity of bortezomib, a proteasome inhibitor, has not yet been elucidated, although tumor lysis syndrome (TLS) associated with multiple myeloma (MM) has been reported to increase after introduction of the drug. This study compared the incidence and risk factors for acute kidney injury (AKI) and TLS in patients with MM after bortezomib-b...
Guevara-Ramírez, Patricia Cadena-Ullauri, Santiago Paz-Cruz, Elius Tamayo-Trujillo, Rafael Ruiz-Pozo, Viviana A. Zambrano, Ana Karina
Published in
Frontiers in Microbiology
Hematologic neoplasms represent 6.5% of all cancers worldwide. They are characterized by the uncontrolled growth of hematopoietic and lymphoid cells and a decreased immune system efficacy. Pathological conditions in hematologic cancer could disrupt the balance of the gut microbiota, potentially promoting the proliferation of opportunistic pathogens...
Antar, Ahmad Szallasi, Arpad Imataki, Osamu
Published in
Frontiers in Oncology
